Opko Health (NASDAQ: OPK) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Volatility and Risk

Opko Health has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals has a beta of 3.31, suggesting that its share price is 231% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Opko Health and Eyegate Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opko Health 0 2 6 0 2.75
Eyegate Pharmaceuticals 0 0 4 0 3.00

Opko Health presently has a consensus price target of $14.81, suggesting a potential upside of 116.40%. Eyegate Pharmaceuticals has a consensus price target of $7.33, suggesting a potential upside of 554.82%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eyegate Pharmaceuticals is more favorable than Opko Health.

Institutional & Insider Ownership

22.5% of Opko Health shares are owned by institutional investors. Comparatively, 13.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. 40.2% of Opko Health shares are owned by company insiders. Comparatively, 24.6% of Eyegate Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Opko Health and Eyegate Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opko Health -6.52% -3.67% -2.78%
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%

Earnings & Valuation

This table compares Opko Health and Eyegate Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opko Health $1.18 billion 3.25 -$17.02 million ($0.17) -40.26
Eyegate Pharmaceuticals $767,481.00 25.10 -$13.31 million ($1.30) -0.86

Eyegate Pharmaceuticals has higher revenue, but lower earnings than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Eyegate Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Opko Health beats Eyegate Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Opko Health

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.